Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Imidacloprid + pyriproxyfen is a combination topical antiparasitic drug used in veterinary medicine, primarily for dogs and cats, to treat and prevent flea infestations and, in some cases, lice. **Imidacloprid** is a neonicotinoid insecticide that acts as a nicotinic acetylcholine receptor agonist, causing paralysis and death in adult fleas and lice. **Pyriproxyfen** is an insect growth regulator (IGR) that mimics juvenile insect hormones, inhibiting the development and maturation of flea eggs and larvae, thereby breaking the flea life cycle. The product is usually formulated as a spot-on solution applied to the animal’s skin monthly. It is distinct from other combinations that include permethrin, which are only for dogs[2][9][11][13].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on imidacloprid + pyriproxyfen.